Henrika Jodeleit - Concepedia

Author

Henrika Jodeleit

Ludwig-Maximilians-Universität München

Also Known As

H Jodeleit, Henrika Jodeleit, Jodeleit, Henrika

Publications

131

Citations

H-Index

Concepts

All Affiliations

Ludwig-Maximilians-Universität München Bavarian State Research Center for Agriculture University of Würzburg Sanofi (Germany)LMU Klinikum

About

Henrika Jodeleit is an author at Ludwig-Maximilians-Universität München specializing in immunology, autoimmunity, and chronic inflammatory diseases.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	59
2	Immunology	3	3	59
3	Pathology	3	3	59
4	Allergy	2	2	39
5	Gastroenterology	1	1	25

Henrika Jodeleit

Publications

131

Citations

H-Index

Page 1

	Year	Citations
Autoantibodies as diagnostic markers and potential drivers of inflammation in ulcerative colitis Henrika Jodeleit, Lisa Milchram, Regina Soldo, PLoS ONE Chronic Inflammatory DiseasesImmunodeficienciesImmunologyGastroenterologyPathology	2020	25
CD1a-Expressing Monocytes as Mediators of Inflammation in Ulcerative Colitis O Al-amodi, Henrika Jodeleit, Florian Beigel, Inflammatory Bowel Diseases	2018	21
A mouse model for ulcerative colitis based on NOD-<i>scid</i> IL2R γnull mice reconstituted with peripheral blood mononuclear cells from affected individuals Pia Palamides, Henrika Jodeleit, Michael Föhlinger, Disease Models & Mechanisms Chronic Inflammatory DiseasesImmune RegulationImmunologyPathologyInnate Immunity	2016	20
Targeting ulcerative colitis by suppressing glucose uptake with ritonavir Henrika Jodeleit, O Al-amodi, J Caesar, Disease Models & Mechanisms	2018	19
Design and validation of a disease network of inflammatory processes in the NSG-UC mouse model Henrika Jodeleit, Pia Palamides, Florian Beigel, Journal of Translational Medicine	2017	18
The Combination of Patient Profiling and Preclinical Studies in a Mouse Model Based on NOD/Scid IL2Rγ null Mice Reconstituted With Peripheral Blood Mononuclear Cells From Patients With Ulcerative Colitis May Lead to Stratification of Patients for Treatment With Adalimumab Henrika Jodeleit, J Caesar, C Villarroel Aguilera, Inflammatory Bowel Diseases	2019	14
Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells Henrika Jodeleit, Paula Winkelmann, J Caesar, Disease Models & Mechanisms Chronic Inflammatory DiseasesImmunodeficienciesImmunologyImmune RegulationPathology	2020	14

Page 1